of pre-clinical and clinical programs have
genetic support
A mix of
innovative molecules, potential
new indications, and biosimilars

A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.

Download Pipeline Chart

*   Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

   Amgen has an additional three biosimilar programs in development which are undisclosed at this time.

**   Tradename provisionally approved by the United States Food and Drug Administration.